1-8 of 8
Peter Presgrave
Close
Sort by
Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Deborah L White, Jacqueline A Rehn, Caitlin E Schutz, Susan L Heatley, Laura N Eadie, Ashlee Thomson, Elyse C Page, Michael Osborn, Shane Gangatharan, Ashley P Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol CY Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Stephen Robert Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla-Pozza, David T Yeung, Matthew Greenwood
Journal: Blood
Blood (2023) 142 (Supplement 1): 1609.
https://doi.org/10.1182/blood-2023-178473
Published: 2023
Journal Articles

In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

John E. Pimanda, Julie A.I. Thoms, Henry R. Hampton, Sarah Davidson, Swapna Joshi, Chowdhury H. Sarowar, Xin Ying Lim, Andrea C. Nunez, Purvi M. Kakadia, Russell Pickford, Mark Raftery, Sally Hough, Griselda Buckland, Michelle Bailey, Yuvaraj Ghodke, Noorul Absar, Lachlin Vaughan, Leonardo Pasalic, Chun Yew Fong, Melita Kenealy, Devendra Hiwase, Rohanna Stoddart, Soma Mohammed, Linda Lee, Freda H. Passam, Kevin Spring, Kristy K. Skarratt, Patricia Rebeiro, Stephen R Larsen, Peter Presgrave, William S Stevenson, Silvia Ling, Campbell Tiley, Stephen Fuller, Fernando Roncolato, Anoop Kumar Enjeti, Dirk Hoenemann, Charlotte Lemech, Stefan K. Bohlander, Jake Olivier, Mark Hertzberg, Ashwin Unnikrishnan, Mark N. Polizzotto
Journal: Blood
Blood (2022) 140 (Supplement 1): 6927–6929.
https://doi.org/10.1182/blood-2022-157634
Published: 2022
Journal Articles

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Matthew Greenwood, Shane Gangatharan, Michael Philip Osborn, Ashley P Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Philip McCloud, Stephen R Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla Pozza
Journal: Blood
Blood (2022) 140 (Supplement 1): 8971–8972.
https://doi.org/10.1182/blood-2022-168568
Published: 2022
Journal Articles

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Judith Trotman, Peter Presgrave, Duncan P. Carradice, Douglas Stuart Lenton, Maher Gandhi, Tara Cochrane, Xavier Badoux, Gloria Nkhoma, Belinda Butcher, Michael Fulham, Anna Johnston
Journal: Blood
Blood (2021) 138 (Supplement 1): 2428.
https://doi.org/10.1182/blood-2021-146343
Published: 2021
Journal Articles

In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial

Ashwin Unnikrishnan, PhD, Xin Ying Lim, PhD, Swapna Joshi, Andrea C. Nunez, PhD, Lachlin Vaughan, MBBS, BSc, FRACP, FRCPA, Russell Pickford, PhD, Sally Hough, Sarah Davidson, Chun Fong, Melita Kenealy, MD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Leonardo Pasalic, MBBS, PhD, Soma Mohammed, Linda Lee, PhD, Freda H. Passam, MD PhD, Kevin Spring, PhD, Patricia Rebeiro, MD, Silvia Ling, MBBS, PhD, Stephen Fuller, MBBS, PhD, Peter Presgrave, MBBS, Fernando Roncolato, BMed, FRACP, FRCPA, Stephen Larsen, MBBS, PhD FRACP, FRCPA, Anoop K Enjeti, MBBS,FRCPA, FRACP,PhDMD,MRCP, William S. Stevenson, MBBS, PhD, Campbell Tiley, MBBS, FRACP, Peter J Campbell, Charlotte Lemech, MD FRACP, Jake Olivier, PhD, Mark Hertzberg, MD MBBS, PhD, Mark N. Polizzotto, MBBS, FRACP, FRCPA, John Pimanda, MBBS, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4247.
https://doi.org/10.1182/blood-2019-123921
Published: 2019
Journal Articles

Evaluation of Pharmacokinetic-Based Dose Predictions of High Dose Melphalan in Patients with Myeloma

Judith Trotman, MBChB, Peter J. Shaw, MBBS, MA, FRACP, Campbell Tiley, MBBS,FRACP, FRCPA, Sundra Ramanathan, MBBS FRCPA FRACP, Andrew P Grigg, MBBS MD, Stephen Robert Larsen, MBBS PhDFRCPA FRACP, Peter Presgrave, MBBS, PhD FRACP, FRCPA, Yiu-Lam Kwan, MBBS, FRACP, FRCPA, Elizabeth Newman, RN, Christa Nath, BSC (Hons), PhD
Journal: Blood
Blood (2015) 126 (23): 4314.
https://doi.org/10.1182/blood.V126.23.4314.4314
Published: 2015
Journal Articles

Lower Drug Exposure Is Related to Renal Function and Results in Inferior Survival: A Pharmacokinetic Study of High Dose Melphalan in Myeloma

Judith Trotman, MBChB, Peter J. Shaw, MBBS, MA, Douglas E Joshua, MBBS, DPhil, Yiu-Lam Kwan, MBBS, Campbell Tiley, MBBS, FRACP, FRCPA, Peter Presgrave, MBBS, PhD, Ian H. Kerridge, MBBS, MPhil, Christa Nath, BSc (Hons), PhD
Journal: Blood
Blood (2012) 120 (21): 1979.
https://doi.org/10.1182/blood.V120.21.1979.1979
Published: 2012
Journal Articles

The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).

Melita K Kenealy, MBBS, FRACP, FRCPA, John F Seymour, MBBS, PhD, FRACP, Cowan Linda, Alvin Milner, Pratyush Giri, Shir-Jing Ho, MBBS, FRACP, FRCPA, Warwick Benson, Andrew Nicol, MBBS, FRCPA, FRACP, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Ian Prosser, MBBS, FRACP, FRCPA, PhD, Craig Underhill, MBBS, FRACP, Ilona Cunningham, Anthony K. Mills, MBBS, FRACP, FRCPA, Jeffrey Szer, MBBS, FRACP, Peter Presgrave, MBBS, FRACP, FRCPA, PhD, Robin Filshie, MBChB, FRACP, FRCPA, PhD
Journal: Blood
Blood (2009) 114 (22): 1749.
https://doi.org/10.1182/blood.V114.22.1749.1749
Published: 2009